Show Summary Details
Page of

Dialysis-associated amyloidosis 

Dialysis-associated amyloidosis
Dialysis-associated amyloidosis

T. Bardin

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 02 August 2021

In 1978, Kenzora reported for the first time the identification of amyloid deposition in a carpal tunnel biopsy specimen from a patient undergoing hemodialysis. From this time, dialysis-associated amyloidosis has been recognized as an increasingly significant problem in renal failure patients maintained on long-term dialysis therapies. Deposits involve mainly articular and peri-articular tissues resulting in a disabling arthropathy, the frequency of which increases with length of survival upon dialysis. Amyloid arthropathy is at present considered as one of the main factors limiting the quality of life of long-term survivors. Moreover, systemic deposition and neurological compromise following destructive involvement of spine are rare, but life-threatening complications. This review will attempt to picture the features of the disease and to differentiate them from articular symptoms of other etiologies in dialysis patients.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.